Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

- Company on Target to File NDA in Second Quarter of 2008 -

CORONA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced positive results today from its Phase 3 study of oxybutynin topical gel (OTG) in patients with overactive bladder (OAB). The study met its primary endpoint of a statistically significant reduction in incontinence episodes, and secondary endpoints of reduction in frequency and increases in void volume compared with placebo, while demonstrating a low incidence of side effects.

"We are extremely encouraged with the results from this trial which will support our NDA submission, and we are on track to file with FDA in the second quarter of 2008," said Paul Bisaro, Watson's President and Chief Executive Officer. "Additionally, we have the potential to introduce the first gel formulation for the treatment of overactive bladder in 2009."

"Offering patients the ease and comfort of a daily gel for the treatment of OAB may provide greater patient acceptability and persistence on treatment," said Peter K. Sand, M.D., director of the Evanston Continence Center, Evanston Northwestern Healthcare, Northwestern University, Feinberg School of Medicine and Professor of Obstetrics and Gynecology and Director of the Division of Urogynecology, Evanston, IL.

It is well recognized that transdermal delivery of oxybutynin is a safe and effective treatment for OAB. By delivering oxybutynin transdermally, first-pass gastric and hepatic metabolism is bypassed, which is believed to result in lower anticholinergic side effects such as dry mouth and constipation. These side effects result in a significant level of patient non-compliance a
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... Md., Dec. 1 Vanda Pharm...ion in The Lancet , one of the world,s leading me...novel circadian regulator, experimental compound t...am et al(1) is entitled "Melatonin agonist tasimel...time shift: two randomised controlled multicentre ...
(Date:12/1/2008)...IS, Dec. 1 Roche announced today t...ferences in perceived pain and,discomfort associa...ood,glucose monitoring systems and lancing device...cated that, overall, the ACCU-CHEK Aviva and ACCU-...s and the ACCU-CHEK Multiclix, ACCU-CHEK,Softclix...
(Date:12/1/2008)...inence is still the best policy , , ROCHES...w study from Mayo Clinic finds the use of the drug...lic hepatitis, an acute inflammation of the liver ...sults of the study are published in the December i...nal.org/ ). , , VIDEO ALERT: Additional au...
(Date:12/1/2008)...nce Call Scheduled for Tuesday, December 9 at 11:0... , , SOUTH SAN FRANCISCO, Calif., Dec. 1 ..., Inc. (Nasdaq: SNSS ), a biopharmaceutical comp...on of new oncology therapeutics, today announced n...loid leukemia (AML) will be presented during the 5...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3A bees future as queen or worker may rest with parasitic fly 4223 1A bees future as queen or worker may rest with parasitic fly 4223 2Nu Skin Enterprises and Toyo Bio Pharma Enter Agreement for Joint Product Research and Development 24435 1Nu Skin Enterprises and Toyo Bio Pharma Enter Agreement for Joint Product Research and Development 24435 2Healthcare Executives Well Rewarded for Their Work 24431 1Healthcare Executives Well Rewarded for Their Work 24431 2Hypnosis shown to reduce symptoms of dementia 24427 1
...cokinetics and Dose Proportionality of,Company,s O...tics,Journal -, LAVAL, QC, June 29, 2007 /PRNewswi...t it will present a poster discussing the dose,tit...t the 3rd,International Forum on Pain Medicine to ...a. , The poster compares two different titration s...
...2007: Chi-Med, the Hutchison Whampoa backed pharma...itive results for its Phase II,proof-of-concept st...litis, a form of inflammatory bowel disease. The ...tolerated and showed an,equivalent drop in clinica..., the current first-line standard of care in,mild-...
Other Medicine Technology:Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine 2Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine 3Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 2Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 3Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 4Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 5Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 6Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 7Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 8
(Date:12/2/2008)...es that the SouthEast Alaska Regional Health Conso... Rhapsody™ Integration Engine to help the di...acy, laboratory and business programs communicate ...ity to statewide systems such as VacTrAK (the Stat...MIS and clinical documentation tool used by substa...
(Date:12/2/2008)...Population Services International (PSI) is launchi...ally reduce the number of African children dying e...ree artemisinin-based combination therapies (ACT) ...ildren suspected of having malaria. This quick-res...etermine if it reduces the number of African child...
(Date:12/1/2008)...Toy Puppies to the Obama Daughters , , WASH... been made of President-Elect Obama,s first promis...ughter,s asthma and allergies, and timing issues, .... So, in the meantime, the Asthma and Allergy Fou...mp; allergy friendly" toy puppies to the Obama chi...
(Date:12/1/2008)...tomography (CT) colonography, also known as virtua... diseases at oncecolorectal cancer and osteoporosi...0. Results of the study will be presented today at... North America (RSNA). , "With CT colonography, ... were able to identify patients with osteoporosis,...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...ain medications widely prescribed for rotator cuff...or cuff is composed of the muscles and tendons tha...it to the shoulder joint. The research involved 18...repair surgery. One-third of the rats were treated...
...antiretroviral therapy HAART, the cytomegalovirus ...ortunistic// infections that spread out of control...shorter time to death. Researchers assessed CMV s...HIV using a standard test. Investigators followed ...
...reened for cervical cancer, according to a new stu...routine // Pap smears are unnecessary for women wh...ancerous diseases. Since most of these women no lo...r cervical cancer. A survey done by researchers on...
...ption may be partly to blame for patients sufferin...ainly caused // by alcohol abuse and gall stones. ...nal pain, often accompanied by nausea and vomiting.... Researchers say pancreatitis has a poor prognosi...
Other Medicine News:
...The new Finnpipette Focus from Thermo Labsystems w...h uncompromising performance. Advanced features s...lume adjustment on microvolumes help to define thi...new interchangeable handle plate offers a custom f...
Enhanced drug and formulary reference with integrated ID treatment guide and tools. Increase patient safety and satisfaction with our premium drug reference.
Designed to inform decision making, PatientKeeper's Clinical Results delivers complete patient data on demand. Clinicians can rely on immediate access to lab results, medication profiles, microbiolog
The SJM Tailor annuloplasty ring, a fully flexible ring, is constructed of a barium-impregnated silicone strip covered with a knitted polyester sewing cuff.
Medicine Products: